Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vivus Inc (VVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,379
  • Shares Outstanding, K 106,020
  • Annual Sales, $ 65,370 K
  • Annual Income, $ -30,510 K
  • 36-Month Beta 0.61
  • Price/Sales 0.62
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.30
  • Most Recent Earnings -0.06 on 11/07/17
  • Next Earnings Date 05/02/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.33 +11.24%
on 04/02/18
0.43 -14.63%
on 04/18/18
-0.06 (-13.62%)
since 03/23/18
3-Month
0.33 +11.24%
on 04/02/18
0.60 -38.82%
on 03/13/18
-0.08 (-18.42%)
since 01/25/18
52-Week
0.33 +11.24%
on 04/02/18
1.38 -73.40%
on 06/07/17
-0.67 (-64.70%)
since 04/25/17

Most Recent Stories

More News
Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?

VIVUS (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

VVUS : 0.38 (+5.56%)
Quotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and Zosano Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on VRTX, VVUS, VYGR, and ZSAN which can be accessed for free by signing up to www.wallstequities.com/registration....

VVUS : 0.38 (+5.56%)
VYGR : 17.77 (+0.17%)
VRTX : 155.02 (-0.42%)
ZSAN : 4.11 (-1.67%)
Developments in the Obesity Treatment Market

According to Grand View Research, the global obesity treatment market was valued at USD 3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. The demand for weight management continues to...

OBLN : 3.78 (+1.61%)
BICX : 0.1238 (+7.75%)
VVUS : 0.38 (+5.56%)
ZFGN : 6.29 (-0.16%)
RSLS : 0.55 (-6.78%)
Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and VIVUS

NEW YORK, NY / ACCESSWIRE / February 9, 2018 / U.S. markets continued to plunge alongside rising interest rates on Thursday. The Dow Jones Industrial Average dropped 4.15 percent to close at 23,860.46,...

VVUS : 0.38 (+5.56%)
ARNA : 40.10 (+0.22%)
Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on SPPI, TLGT, VRTX, and VVUS which can be accessed for free by signing up to www.wallstequities.com/registration....

SPPI : 16.94 (-2.31%)
TLGT : 3.47 (-0.58%)
VVUS : 0.38 (+5.56%)
VRTX : 155.02 (-0.42%)
Orexigen Struggles as Contrave Commercialization Costs Rise

Orexigen (OREX) hurt by higher commercialization costs related to Contrave.

OREX : 0.22 (-34.41%)
NVO : 46.82 (-0.55%)
VVUS : 0.38 (+5.56%)
ARNA : 40.10 (+0.22%)
VIVUS Announces Change in Leadership

Board Member Thomas B. King appointed interim CEO; Seth Fischer steps down as CEO effective December 31, 2017

VVUS : 0.38 (+5.56%)
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

VVUS : 0.38 (+5.56%)
RDY : 31.67 (-2.19%)
EXEL : 20.72 (+1.57%)
TEVA : 17.22 (-1.94%)
VIVUS Reports Third Quarter 2017 Financial Results

CAMPBELL, CA--(Marketwired - November 07, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing...

VVUS : 0.38 (+5.56%)
VIVUS Reports Third Quarter 2017 Financial Results

CAMPBELL, CA--(Marketwired - November 07, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing...

VVUS : 0.38 (+5.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity...

See More

Key Turning Points

2nd Resistance Point 0.41
1st Resistance Point 0.38
Last Price 0.38
1st Support Level 0.35
2nd Support Level 0.34

See More

52-Week High 1.38
Fibonacci 61.8% 0.98
Fibonacci 50% 0.86
Fibonacci 38.2% 0.73
Last Price 0.38
52-Week Low 0.33

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar